

1 **Systematic review of genotype-stratified treatment for monogenic insulin resistance**

2

3 Robert K. Semple^{1,2}, Kashyap A. Patel^{3,4}, Sungyoung Auh⁵, ADA/EASD PMDI⁶, Rebecca J. Brown⁷

4

5 **Affiliations**

6 ¹ Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

7 ² MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh,
8 UK

9 ³ Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.

10 ⁴ Department of Diabetes and Endocrinology, Royal Devon and Exeter NHS Foundation Trust, Exeter,
11 UK.

12 ⁵ Office of the Clinical Director, National Institute of Diabetes and Digestive and Kidney Diseases,
13 National Institutes of Health, Bethesda, MD, USA

14 ⁶ American Diabetes Association/European Association for the Study of Diabetes Precision
15 Medicine in Diabetes Initiative

16 ⁷ National Institute of Diabetes and Digestive and Kidney Diseases. National Institutes of Health.
17 Bethesda, MD, USA.

18

19 **Correspondence**

20 Rebecca J. Brown, MD, MHSc

21 Building 10-CRC, Room 6-5942

22 10 Center Drive

23 Bethesda, MD 20892

24 Email: brownrebecca@niddk.nih.gov

25 Voicemail: 301-594-0609

26 Fax: 301-480-0365

27

28 **Keywords**

29 Precision Medicine, Diabetes, Genetics, Insulin Resistance, Lipodystrophy, Insulin Receptor,

30 Metreleptin, Leptin, thiazolidinediones, Insulin-like growth factor-1

31

32 **Running Title**

33 Precision Treatment of Monogenic Insulin Resistance

34

35 **Word counts** Abstract: 297 words; Main Text: 3,501 words

36 **Abstract**

37

38 **Objective:** To assess the effects of pharmacologic and/or surgical interventions in monogenic insulin
39 resistance (IR), stratified by genetic aetiology.

40 **Design:** Systematic review.

41 **Data sources:** PubMed, MEDLINE and Embase, from 1 January 1987 to 23 June 2021.

42 **Review methods:** Studies reporting individual-level effects of pharmacologic and/or surgical
43 interventions in monogenic IR were eligible. Individual subject data were extracted and duplicate
44 data removed. Outcomes were analyzed for each affected gene and intervention, and in aggregate
45 for partial, generalised and all lipodystrophy.

46 **Results:** 10 non-randomised experimental studies, 8 case series, and 21 single case reports met
47 inclusion criteria, all rated as having moderate or serious risk of bias. Metreleptin was associated
48 with lower triglycerides and hemoglobin A1c in aggregated lipodystrophy (n=111), in partial
49 lipodystrophy (n=71) and generalised lipodystrophy (n=41)), and in *LMNA*, *PPARG*, *AGPAT2* or *BSCL2*
50 subgroups (n=72,13,21 and 21 respectively). Body Mass Index (BMI) was lower after treatment in
51 partial and generalised lipodystrophy overall, and in *LMNA* or *BSCL2*, but not *PPARG* or *AGPAT2*
52 subgroups. Thiazolidinedione use was associated with improved hemoglobin A1c and triglycerides in
53 aggregated lipodystrophy (n=13), improved hemoglobin A1c only in the *PPARG* subgroup (n=5), and
54 improved triglycerides only in the *LMNA* subgroup (n=7). In *INSR*-related IR, use of rhIGF-1, alone or
55 with IGFBP3, was associated with improved hemoglobin A1c (n=15). The small size or absence of all
56 other genotype-treatment combinations precluded firm conclusions.

57 **Conclusions:** The evidence guiding genotype-specific treatment of monogenic IR is of low to very low
58 quality. Metreleptin and Thiazolidinediones appear to have beneficial metabolic effects in
59 lipodystrophy, and rhIGF-1 appears to lower hemoglobin A1c in *INSR*-related IR. For other
60 interventions there is insufficient evidence to assess efficacy and risks either in aggregated
61 lipodystrophy or in genetic subgroups. There is a pressing need to improve the evidence base for
62 management of monogenic IR.

63

64 **Introduction**

65 Diabetes caused by single gene changes is highly heterogeneous in molecular
66 aetiopathogenesis. It may be grouped into disorders featuring primary failure of insulin
67 secretion, and disorders in which insulin resistance (IR), often severe, predates secondary
68 failure of insulin secretion and diabetes. Monogenic IR is itself heterogeneous,
69 encompassing primary lipodystrophy syndromes, primary disorders of insulin signalling, and
70 a group of conditions in which severe IR is part of a more complex developmental syndrome
71 ¹.

72 Monogenic IR is rare but underdiagnosed. The commonest subgroup is formed by
73 genetic lipodystrophy syndromes ^{2,3}. Recent analysis of a large clinical care cohort
74 unselected for metabolic disease suggested a clinical prevalence of lipodystrophy of around
75 1 in 20,000, with a prevalence of plausible lipodystrophy-causing genetic variants of around
76 1 in 7,000 ⁴. Monogenic IR is important to recognise, because affected patients are at risk
77 not only of micro- and macrovascular complications of diabetes, but also of complications
78 such as dyslipidemia, pancreatitis, and steatohepatitis, especially in lipodystrophy
79 syndromes ⁵. Non-metabolic complications specific to individual gene defects may also
80 occur, including hypertrophic cardiomyopathy and other manifestations of soft tissue
81 overgrowth ³. Diabetes is also commonly the sentinel presentation of a multisystem
82 disorder, and recognition of complex syndromes in a diabetes clinic may trigger definitive
83 diagnostic testing.

84 The only therapy licensed specifically for monogenic IR is recombinant human
85 methionyl leptin (metreleptin), with licensed indications encompassing a subset of patients
86 with lipodystrophy and inadequate metabolic control ^{6,7}. The current license in the USA is

87 restricted to generalised lipodystrophy, but in Europe it extends to some patients with
88 partial lipodystrophy. A significant proportion of the body of evidence considered in
89 licensing addressed patients ascertained by presence of clinical lipodystrophy, and the role
90 of genetic stratification in precision treatment of lipodystrophy has not been systematically
91 addressed. Many other medications and other treatment options are also widely used in
92 monogenic IR, although not licensed for that specific subgroup. Such use draws on the
93 evidence base and treatment algorithms developed for type 2 diabetes. Several forms of
94 monogenic IR have molecular and/or clinical attributes that suggest potential precision
95 approaches to treatment.

96 We sought now to undertake a systematic review of the current evidence guiding
97 treatment of monogenic IR stratified by genetic aetiology, to assess evidence for differential
98 responses to currently used therapies, to establish gaps in evidence, and to inform future
99 studies. This systematic review is written on behalf of the American Diabetes Association
100 (ADA)/European Association for the Study of Diabetes (EASD) *Precision Medicine in Diabetes*
101 *Initiative* (PMDI) as part of a comprehensive evidence evaluation in support of the
102 2nd International Consensus Report on Precision Diabetes Medicine [Tobias et al, Nat Med].
103 The PMDI was established in 2018 by the ADA in partnership with the EASD to address the
104 burgeoning need for better diabetes prevention and care through precision medicine ⁸.

105

106 **Methods**

107 *Inclusion Criteria and Search Methodology*

108 To assess treatment of severe IR of known monogenic aetiology, with or without
109 diabetes mellitus, including generalised and partial lipodystrophy and genetic disorders of

110 the insulin receptor, we developed, registered and followed a protocol for a systematic
111 review (Prospero ID [CRD42021265365](https://doi.org/10.1101/2023.04.17.23288671); registered July 21, 2021)⁹. The study was reported in
112 accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis
113 (PRISMA) guidelines. Filtering and selection of studies for data extraction were recorded
114 using the Covidence platform (<https://www.covidence.org>, Melbourne, Australia).

115 We searched PubMed, MEDLINE and Embase from 1987 (the year before
116 identification of the first monogenic aetiology of IR) to June 23, 2021 for potentially relevant
117 human studies in English. We used broad search terms designed to capture the
118 heterogeneity of monogenic IR and its treatments. We searched for studies addressing 1.
119 Severe IR due to variant(s) in a single gene OR 2. Congenital generalised or familial partial
120 lipodystrophy due to variant(s) in a single gene. We selected only studies that reported a
121 treatment term, including but not limited to mention of 1. Thiazolidinediones (TZD), 2.
122 Metreleptin, 3. SGLT2 inhibitors, 4. GLP-1 analogues, 5. Bariatric surgery (all types), 6.
123 Recombinant human IGF-1 or IGF-1/IGFBP3 composite, 7. U-500 insulin. No interventions
124 were excluded in the primary search. In addition to the automated search, we hand
125 searched reference lists of relevant review articles. Given the rarity of monogenic IR, no
126 study types were excluded in the initial search. We ultimately considered experimental
127 studies, case reports, and case series. The full search strategy is described in Supplemental
128 Table 1.

129 Study selection for data extraction was performed in two phases, namely primary
130 screening of title and abstract, then full text review of potentially eligible articles. Two
131 authors independently evaluated eligibility, with discrepancies resolved by a third
132 investigator. We excluded publications without original data, such as reviews, editorials, and
133 comments, and those solely addressing severe IR or lipodystrophy of unknown or known

134 non-monogenic aetiology, including HIV-related or other acquired lipodystrophies, or
135 autoimmune insulin receptoropathy (Type B insulin resistance). Studies in which no clear
136 categorical or numerical outcome of an intervention was reported, or in which interventions
137 were administered for less than 28 days were also excluded.

138 *Data extraction and outcome assessments*

139 One author extracted data from each eligible study using data extraction sheets.
140 Data from each study was verified by all 3 authors to reach consensus. Data were extracted
141 from text, tables, or figures. Study investigators were contacted for pertinent unreported
142 data or additional details where possible, most commonly genetic aetiology of insulin
143 resistance in reported patients, and outcome data.

144 Data extracted for each study included first author, publication year, country, details
145 of intervention, duration of follow-up, study design, and number of participants. Subject-
146 level data were extracted for outcomes of interest, including sex, genetic cause of severe
147 insulin resistance (gene name, mono- vs biallelic *INSR* pathogenic variant), phenotypic
148 details of severe IR/lipodystrophic subtype (generalised vs partial lipodystrophy; associated
149 syndromic features). Subject level outcome data for were extracted prior to and after the
150 longest-reported exposure to the intervention of interest for hemoglobin A1c (A1c), body
151 mass index, serum triglyceride, ALT, or AST concentration, any index of liver size or lipid
152 content, and total daily insulin dose. Potential adverse effects of interventions were
153 recorded, including urinary tract infection, genital candidiasis, hypoglycemia, excessive
154 weight loss, pancreatitis, soft tissue overgrowth, and tumor formation.

155

156 *Risk of bias and certainty of evidence assessment*

157 Quality of extracted case reports and case series was assessed using NIH Study
158 Quality Assessment Tools¹⁰. Grading of overall evidence for specific research questions was
159 undertaken as detailed in¹¹.

160

161 *Data synthesis and analysis*

162 Extracted data were managed using Covidence and analysed with SAS version 9.4.
163 Pooled analysis was undertaken for all combinations of genotype and intervention for which
164 sufficient numbers were reported, as well as for aggregated lipodystrophies, and
165 generalized and partial subgroups of lipodystrophy. Generalized Estimating Equation
166 models were used with time as a fixed factor and study as a random factor to examine
167 treatment effects. Serum triglyceride concentrations were analyzed with and without log
168 transformation. Data were summarized using estimated least-squared means with
169 corresponding 95% confidence intervals.

170

171 **Results**

172 **Identification of eligible studies**

173 Initial searching identified 2,933 studies, to which 109 were added from the
174 bibliography of a recent comprehensive review of monogenic lipodystrophy². 248 articles
175 remained after screening of titles and abstracts, and 42 after full text screening (Figure 1).

176

177 **Included studies addressed limited interventions and most had a high risk of bias**

178 The 42 studies analysed, and assessment of their quality are summarised in Table 1
179 and detailed in Supplemental Table 2. Study quality was assessed as being fair in 15 cases
180 and poor in 27 cases, including all case reports. This was primarily due to high risk of bias,

181 particularly related to lack of control group for all studies. Three of the 42 studies included
182 in further analysis included only individuals already described in other reports and were
183 discarded, leaving 39 studies for final analysis. These comprised 10 non-controlled
184 experimental studies, 8 case series and 21 individual case reports (Table 1). No controlled
185 trials were found. Individuals reported in the studies included 90 with partial lipodystrophy
186 (72 due to *LMNA* mutation and 15 due to *PPARG* mutation), 42 with generalized
187 lipodystrophy (21 *AGPAT2*, 21 *BSCL2*, 2 *LMNA*), and 17 with IR due to *INSR* mutation(s).
188 Among the interventions described, only the responses to metreleptin (111 recipients),
189 thiazolidinediones (13 recipients) and rhIGF-1 (alone or as a composite with IGFBP3) (15
190 recipients) were described in more than 5 cases (Table 1). This meant that for the large
191 preponderance of possible genotype-treatment combinations no specific data were
192 recovered (Supplemental Table 3). Full outcome data extracted are summarised in
193 Supplemental Table 4, and subject-level data are shown in Supplemental Figures 1 through
194 8.

195

196 **Metreleptin treatment was associated with improved metabolic control in lipodystrophy**

197 In our registered systematic review plan we posed several subquestions about
198 treatment of monogenic IR subtypes that we felt were tractable. The first related to the
199 risks and benefits (assessed by side effects, A1c, serum triglyceride concentration, body
200 mass index (BMI), and indices of fatty liver) of metreleptin in patients with different
201 monogenic subtypes of lipodystrophy. The response to metreleptin was described in 111
202 people (71 with partial lipodystrophy, 40 with generalized lipodystrophy)¹²⁻²². Metreleptin
203 was administered for 19±20 months (median 12, range 1-108) and was associated with
204 lowering of A1c in aggregated lipodystrophy, in generalized and partial subgroups, and in all

205 genetic subgroups for whom sufficient patients were reported, namely those with *LMNA*,
206 *PPARG*, *AGPAT2* and *BSCL2* mutations (0.5 to 1.5% least square mean reduction) (Level 3
207 evidence, Supplemental Table 4, Figure 2). Metreleptin treatment was also associated with
208 lowering of serum triglyceride concentration in aggregated lipodystrophy, in generalized
209 and partial subgroups, and in those with *LMNA*, *PPARG*, *AGPAT2* and *BSCL2* mutations (92 to
210 1760 mg/dL least square mean reduction for analyses of untransformed data) (Level 3
211 evidence, Supplemental Table 4, Figure 2). BMI was lower after treatment in aggregated
212 lipodystrophy, in generalized and partial subgroups, and in those with *LMNA* or *BSCL2*
213 mutations, but not *PPARG* or *AGPAT2* mutations (Level 3 evidence, Supplemental Table 4,
214 Figure 2). Liver outcomes reported were too heterogeneous to analyse in aggregate. Only a
215 single adverse event, namely hypoglycemia, was reported.

216

217 **Thiazolidinedione treatment showed variable efficacy in limited studies**

218 We next addressed the evidence of risks and benefits of thiazolidinediones (TZDs) in
219 patients with lipodystrophy. We were specifically interested in any evidence of a greater or
220 lesser response in partial lipodystrophy caused by *PPARG* variants than in other
221 lipodystrophy subtypes, as TZDs are potent ligands for the gene product of the *PPARG* gene,
222 the master regulator of adipocyte differentiation. The response to TZDs was described in
223 only 13 people, however (12 FPLD, 1 CGL)²³⁻³². TZDs were administered for 29±28 months
224 (median 24, range 2-96). TZD use was associated with improved A1c in aggregated
225 lipodystrophy (least square mean reduction 2.2%) and in *PPARG*-related but not *LMNA*-
226 related partial lipodystrophy (Level 4 evidence, Supplemental Table 4, Figure 3). Serum
227 triglyceride concentration decreased in aggregated lipodystrophy and in those with *LMNA*-

228 related but not *PPARG*-related partial lipodystrophy (Level 4 evidence, Supplemental Table
229 4, Figure 3). No adverse events were reported.

230

231 **rhIGF-1 treatment in *INSR*-related IR was associated with improvement in A1c**

232 Our last specific question related to the risks (e.g. tumors, hypoglycemia, cardiac
233 hypertrophy, other soft tissue overgrowth) and benefits (assessed by A1c) of recombinant
234 human IGF-1 (rhIGF-1) or IGF-1/IGFBP3 composite in patients with pathogenic *INSR* variants.
235 The response to rhIGF-1 was described in 15 people with pathogenic *INSR* variants for a
236 mean of 50±86 months (median 12, range 1-288)³³⁻⁴². In *INSR*-related IR, we found that use
237 of rhIGF-1, alone or as a composite with IGFBP3, was associated with improvement in A1c,
238 and this was true also in subgroups with monoallelic and biallelic variants (1 to 2% least
239 square mean reduction, Level 4 evidence, Supplemental Table 4, Figure 4). One instance of
240 increased soft tissue overgrowth and two episodes of hypoglycemia was reported.

241

242 **Many questions about genotype-stratified treatment were not addressed**

243 While many other interesting and clinically relevant questions arise about other
244 potential genotype-specific responses to therapy in monogenic IR, the small size or absence
245 of other genotype by treatment groups precluded the drawing of conclusions about risks
246 and benefits, including for very widely used medications such as metformin^{25,43-45}, newer
247 agents commonly used in type 2 diabetes including SGLT2 inhibitors^{46,47} and GLP1 agonists,
248 and non pharmacologic interventions such as bariatric surgery⁴⁸⁻⁵⁰.

249

250 **Discussion**

251 Thirty-five years since *INSR* mutations were identified in extreme IR ^{51,52}, and 23
252 years since the first monogenic cause of lipodystrophy was reported ⁵³, many different
253 forms of monogenic IR are known ^{1-3,54}. These are associated with substantial early
254 morbidity and mortality, ranging from death in infancy to accelerated complications of
255 diabetes and fatty liver disease in adulthood, depending on the genetic subtype. Several
256 opportunities for genotype-guided, targeted treatment are suggested by the causal genes,
257 and so we set out to review the current evidence guiding treatment of monogenic IR
258 stratified by genetic aetiology. We found a paucity of high-quality evidence (all level 3 to 4).
259 No controlled trials of any intervention were identified, and there was substantial
260 heterogeneity of study populations and intervention regimens, even for the same
261 interventional agent.

262 The evidence which we did find, from a small number of uncontrolled experimental
263 studies, augmented by case series and numerous case reports, suggest that metreleptin
264 offers metabolic benefits across different lipodystrophy subtypes, in keeping with its
265 licensing for use in some patients with lipodystrophy in both Europe and the USA. Notably,
266 the evidence base considered by licensing authorities was larger than the one we present,
267 including many studies of phenotypically ascertained lipodystrophy that included acquired
268 or idiopathic disease. In contrast we have addressed solely individuals with lipodystrophy
269 caused by variation in a single gene. The limited data we identified do not clearly support
270 differential effects among different monogenic lipodystrophy subgroups, but for many
271 subtypes numbers reported are very small. Moreover although responses appear
272 comparable for partial and generalised lipodystrophy, this is highly likely to reflect selection
273 bias in studies of partial lipodystrophy towards those with more severe metabolic
274 complications and lower baseline serum leptin concentrations.

275 A clear opportunity for precision diabetes therapy in monogenic IR is offered by the
276 IR and lipodystrophy caused by mutations in *PPARG*, which encodes the target for
277 thiazolidinediones (TZDs) such as pioglitazone^{55,56}. *PPARG* is a nuclear receptor that serves
278 as the master transcriptional driver of adipocyte differentiation, and so as soon as *PPARG*
279 mutations were identified to cause severe IR, there was interest in the potential of TZDs as
280 specific treatments. Although we found small scale evidence supporting greater A1c
281 reduction with TZDs in *PPARG* vs *LMNA*-related lipodystrophy, only 5 patients with *PPARG*-
282 related lipodystrophy in whom TZD effects were clearly described were reported, and
283 responses were inconsistent. Thus, it remains unclear whether people with IR due to *PPARG*
284 variants are more or indeed less sensitive to TZDs than people with other forms of
285 lipodystrophy. Loss-of-function *PPARG* mutations are the second commonest cause of
286 familial partial lipodystrophy², and the function of coding missense variants in *PPARG* has
287 been assayed systematically to accelerate genetic diagnosis⁵⁷, so the opportunity to test
288 genotype-related therapy in *PPARG*-related IR seems particularly tractable in future.

289 Other obvious questions about targeted treatment of monogenic, lipodystrophic IR
290 are not addressed by current evidence. Important examples relate to the risks and benefits
291 of treatments used in type 2 diabetes such as GLP-1 agonists and SGLT2 inhibitors. It is
292 rational to suppose that these medications, which decrease weight as well as improving
293 glycaemia in those with raised BMI and diabetes, may also be efficacious in lipodystrophy
294 even where BMI is normal or only slightly raised. This is because in both situations adipose
295 storage capacity is exceeded, leading to “fat failure”. It is the offloading of overloaded
296 adipose tissue, rather than the baseline BMI/adipose mass, which underlies the efficacy of
297 therapy. However GLP-1 agonists are contraindicated in those with prior pancreatitis, while
298 SGLT2 inhibitor use can be complicated by diabetic ketoacidosis. In untreated lipodystrophy

299 pancreatitis is common, yet this is due to hypertriglyceridaemia, which is likely to be
300 improved by GLP-1 agonist use, while excessive supply of free fatty acids to the liver may
301 promote ketogenesis. Thus assessment of both classes of drug in lipodystrophy and its
302 genetic subgroups will be important to quantify risks and benefits, which may be distinct to
303 those in obesity-related diabetes.

304 A further question we prespecified related to the use of rhIGF1 in people with severe
305 IR due to *INSR* mutations. This use of rhIGF-1 was first described in recessive *INSR* defects in
306 the early 1990s ⁴², based on the rationale that IGF-1 activates a receptor and signalling
307 pathway very closely similar to those activated by insulin. Based on case reports, case series
308 and narrative reviews, rhIGF-1 is now commonly used in neonates with extreme IR due to
309 biallelic *INSR* mutations, although, unlike metreleptin in lipodystrophy, this use is still
310 unlicensed. Our review of published data is consistent with glycaemic benefits of rhIGF-1,
311 alone or in composite form with its binding protein IGFBP3, in *INSR* mutations.
312 Nevertheless, such studies are challenging to interpret and are potentially fraught with bias
313 of different types, particularly publication bias favouring positive outcomes. Responses to
314 rhIGF1 are also challenging to determine in uncontrolled studies as small differences in
315 residual function of mutated receptors can have substantial effects on the severity and
316 natural history of the resulting IR, yet relatively few *INSR* mutations have been studied
317 functionally. This underlines the narrow nature of, and significant residual uncertainty in,
318 the evidence base for use of rhIGF-1 in monogenic IR.

319 There are several reasons why important questions about precision treatment of
320 monogenic IR have not been settled. Although severe autosomal recessive IR is usually
321 detected in infancy, commoner dominant forms of monogenic IR are often diagnosed
322 relatively late, often only after years of management based on presumptive diagnoses of

323 type 2 or sometimes type 1 diabetes. Initial management as type 2 diabetes means that by
324 the time a clinical and then genetic diagnosis is made, most patients have been treated with
325 agents such as metformin, and increasingly SGLT2 inhibitors or GLP-1 agonists, outside trial
326 settings. It is not clear that harm is caused by such use of drugs with well-established safety
327 profiles and efficacy in type 2 diabetes, but the lack of systematic data gathering precludes
328 identification of specific drug-genotype interactions. Moreover, because attempts to gather
329 evidence for monogenic IR treatment has tended to focus on high-cost adjunctive therapies
330 such as metreleptin, the evidence base for their use is better developed, although
331 controlled trials are lacking. Licensing of high-cost treatments such as metreleptin in
332 lipodystrophy, while effects of many more commonly used, cheaper drugs with well-
333 established safety profiles lack formal testing in monogenic IR is potentially problematic,
334 skewing incentives and guidelines towards expensive therapy before optimal treatment
335 algorithms have been established.

336 Other challenges in conducting trials in monogenic IR arise from the exquisite
337 sensitivity of IR to exacerbating factors such as puberty, diet, and energy balance. This
338 creates a “signal to noise” problem particularly problematic in uncontrolled studies, in
339 which non-pharmacological components of interventions such as increased support for
340 behavioural change may confound attribution of beneficial outcomes to pharmacological
341 agents tested.

342 The key question now is how the evidence base for managing monogenic severe IR
343 can be improved in the face of constraints in studying rare, clinically heterogeneous, and
344 geographically dispersed patients who are often diagnosed late with a condition that is
345 exquisitely environmentally sensitive. Growing interest in and development of
346 methodologies for clinical trials in rare disease⁵⁸, including Bayesian methodologies^{59,60},

347 and hybrid single- and multi-site designs⁶¹ offer hope for future filling of evidence gaps. One
348 important and pragmatic opportunity arises from the development of large regional,
349 national and international networks and registries for lipodystrophy (e.g. the Europe-based
350 ECLip registry⁶²), allied to emergence of randomised registry-based trial (RRT) methodology
351^{63,64}. RRTs have attracted increasing interest in several disease areas and are particularly
352 suitable for evaluation of agents with well-established safety profiles. When a simple
353 randomisation tool is deployed in the context of a registry, RRTs can offer rapid, cost-
354 effective recruitment and high external validity (i.e. relevance to “real world” practice). In
355 monogenic IR this would permit questions to be addressed about optimal usage of different
356 “common” medications in different genetic subgroups, including the order of introduction
357 of therapies, and their optimal combinations. The quality of such studies will critically rely
358 on good registry design and quality and completeness of data capture^{63,64}.

359 In summary, severe monogenic IR syndromes are clinically and genetically
360 heterogeneous, with high early morbidity and mortality. However despite opportunities for
361 targeted therapy of some monogenic subgroups based on the nature of the causal gene
362 alteration, the evidence for genotype-stratified therapy is weak. This is in part because of
363 the rarity and frequent late diagnosis of monogenic IR, but also because therapeutic
364 research to date has focused largely on phenotypically ascertained cross cutting diagnoses
365 such as lipodystrophy. We suggest that approaches such as RRTs hold the best hope to
366 answer some of the persisting major questions about precision treatment in monogenic IR.

367

368 **Authors’ declaration of personal interests**

369 R.K.S. has received speaker fees from Eli Lilly, Novo Nordisk, and Amryt. R. J. B. has received
370 research support from Amryt, Third Rock Ventures, Ionis, and Regeneron. K.A.P. and S.A.
371 report no conflicts of interest.

372

373 **Acknowledgements**

374 This research was funded in part, by the Wellcome Trust [Grant WT 210752 to RKS and WT
375 219606 to KAP]. For the purpose of open access, the author has applied a CC0 Public
376 Domain Dedication to any Author Accepted Manuscript version arising from this submission.
377 RJB and SA are supported by the intramural research program of the National Institute of
378 Diabetes and Digestive and Kidney Diseases. The ADA/EASD Precision Diabetes Medicine
379 Initiative, within which this work was conducted, has received the following support: The
380 Covidence license was funded by Lund University (Sweden) for which technical support was
381 provided by Maria Björklund and Krister Aronsson (Faculty of Medicine Library, Lund
382 University, Sweden). Administrative support was provided by Lund University (Malmö,
383 Sweden), University of Chicago (IL, USA), and the American Diabetes Association
384 (Washington D.C., USA). The Novo Nordisk Foundation (Hellerup, Denmark) provided grant
385 support for in-person writing group meetings (PI: L Phillipson, University of Chicago, IL).

386 References

- 387 1 Bonnefond, A. & Semple, R. K. Achievements, prospects and challenges in precision care for
388 monogenic insulin-deficient and insulin-resistant diabetes. *Diabetologia* **65**, 1782-1795 (2022).
389 <https://doi.org/10.1007/s00125-022-05720-7>
- 390 2 Lim, K., Haider, A., Adams, C., Sleight, A. & Savage, D. B. Lipodystrophy: a paradigm for
391 understanding the consequences of "overloading" adipose tissue. *Physiol Rev* **101**, 907-993
392 (2021). <https://doi.org/10.1152/physrev.00032.2020>
- 393 3 Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P. & O'Rahilly, S. Genetic syndromes of severe
394 insulin resistance. *Endocr Rev* **32**, 498-514 (2011). <https://doi.org/10.1210/er.2010-0020>
- 395 4 Gonzaga-Jauregui, C. *et al.* Clinical and Molecular Prevalence of Lipodystrophy in an
396 Unascertained Large Clinical Care Cohort. *Diabetes* **69**, 249-258 (2020).
397 <https://doi.org/10.2337/db19-0447>
- 398 5 Brown, R. J. *et al.* The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society
399 Practice Guideline. *J Clin Endocrinol Metab* **101**, 4500-4511 (2016).
400 <https://doi.org/10.1210/jc.2016-2466>
- 401 6 29 (2013).
- 402 7 Agency, E. M. *Myalepta*
403 <[https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta#authorisation-details-](https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta#authorisation-details-section)
404 [section](https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta#authorisation-details-section)> (2018).
- 405 8 Nolan, J. J. *et al.* ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective
406 and Future Vision for Precision Medicine in Diabetes. *Diabetes Care* **45**, 261-266 (2022).
407 <https://doi.org/10.2337/dc21-2216>
- 408 9 (2021).
- 409 10 *Study Quality Assessment Tools*, <[https://www.nhlbi.nih.gov/health-topics/study-quality-](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)
410 [assessment-tools](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools)> (
- 411 11 Sherifali, D. *et al.* Methods. *Canadian journal of diabetes* **42**, S6-S9 (2018).
412 <https://doi.org/10.1016/j.jcjd.2017.10.002>
- 413 12 Musso, C., Major, M. L., Andres, E. & Simha, V. Metreleptin Treatment in Three Patients with
414 Generalized Lipodystrophy. *Clinical medicine insights. Case reports* **9**, 123-127 (2016).
415 <https://doi.org/10.4137/CCRRep.S40196>
- 416 13 Beltrand, J. *et al.* Resistance to leptin-replacement therapy in Berardinelli-Seip congenital
417 lipodystrophy: an immunological origin. *Eur J Endocrinol* **162**, 1083-1091 (2010).
418 <https://doi.org/10.1530/eje-09-1027>
- 419 14 Vatieer, C. *et al.* Adherence with metreleptin therapy and health self-perception in patients with
420 lipodystrophic syndromes. *Orphanet J Rare Dis* **14**, 177 (2019). [https://doi.org/10.1186/s13023-](https://doi.org/10.1186/s13023-019-1141-2)
421 [019-1141-2](https://doi.org/10.1186/s13023-019-1141-2)
- 422 15 Beltrand, J. *et al.* Metabolic correction induced by leptin replacement treatment in young
423 children with Berardinelli-Seip congenital lipoatrophy. *Pediatrics* **120**, e291-296 (2007).
424 <https://doi.org/10.1542/peds.2006-3165>
- 425 16 Chong, A. Y., Lupsa, B. C., Cochran, E. K. & Gorden, P. Efficacy of leptin therapy in the different
426 forms of human lipodystrophy. *Diabetologia* **53**, 27-35 (2010). [https://doi.org/10.1007/s00125-](https://doi.org/10.1007/s00125-009-1502-9)
427 [009-1502-9](https://doi.org/10.1007/s00125-009-1502-9)
- 428 17 Maeda, M., Maeda, T., Ebihara, K. & Ihara, K. The long-term management of congenital
429 generalized lipodystrophy (Berardinelli-Seip syndrome): the clinical manifestations of Japanese
430 siblings for approximately 20 years. *Clinical pediatric endocrinology : case reports and clinical*
431 *investigations : official journal of the Japanese Society for Pediatric Endocrinology* **28**, 139-145
432 (2019). <https://doi.org/10.1297/cpe.28.139>
- 433 18 Ebihara, K. *et al.* Efficacy and safety of leptin-replacement therapy and possible mechanisms of
434 leptin actions in patients with generalized lipodystrophy. *J Clin Endocrinol Metab* **92**, 532-541
435 (2007). <https://doi.org/10.1210/jc.2006-1546>

- 436 19 Ajluni, N., Dar, M., Xu, J., Neidert, A. H. & Oral, E. A. Efficacy and Safety of Metreleptin in Patients
437 with Partial Lipodystrophy: Lessons from an Expanded Access Program. *Journal of diabetes &*
438 *metabolism* **7** (2016). <https://doi.org:10.4172/2155-6156.1000659>
- 439 20 Sekizkardes, H., Cochran, E., Malandrino, N., Garg, A. & Brown, R. J. Efficacy of Metreleptin
440 Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. *J Clin*
441 *Endocrinol Metab* **104**, 3068-3076 (2019). <https://doi.org:10.1210/jc.2018-02787>
- 442 21 Simha, V. *et al.* Comparison of efficacy and safety of leptin replacement therapy in moderately
443 and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. *J*
444 *Clin Endocrinol Metab* **97**, 785-792 (2012). <https://doi.org:10.1210/jc.2011-2229>
- 445 22 Takeyari, S. *et al.* Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a
446 case report. *Clinical pediatric endocrinology : case reports and clinical investigations : official*
447 *journal of the Japanese Society for Pediatric Endocrinology* **28**, 1-7 (2019).
448 <https://doi.org:10.1297/cpe.28.1>
- 449 23 Chaves, C., Chaves, M., Anselmo, J. & César, R. Successful long-term use of pioglitazone in
450 Berardinelli-Seip lipodystrophy-associated diabetes. *Endocrinol Diabetes Metab Case Rep* **2021**
451 (2021). <https://doi.org:10.1530/edm-20-0183>
- 452 24 Collet-Gaudillat, C., Billon-Bancel, A. & Beressi, J. P. Long-term improvement of metabolic control
453 with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case
454 report. *Diabetes Metab* **35**, 151-154 (2009). <https://doi.org:10.1016/j.diabet.2009.01.001>
- 455 25 Gambineri, A. *et al.* Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C
456 gene is sensitive to thiazolidinediones but not to metformin. *Eur J Endocrinol* **159**, 347-353
457 (2008). <https://doi.org:10.1530/eje-08-0272>
- 458 26 Moreau, F. *et al.* Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a
459 case report. *Diabetes Metab* **33**, 385-389 (2007). <https://doi.org:10.1016/j.diabet.2007.04.005>
- 460 27 Owen, K. R., Donohoe, M., Ellard, S. & Hattersley, A. T. Response to treatment with rosiglitazone
461 in familial partial lipodystrophy due to a mutation in the LMNA gene. *Diabet Med* **20**, 823-827
462 (2003). <https://doi.org:10.1046/j.1464-5491.2003.01034.x>
- 463 28 Simha, V., Rao, S. & Garg, A. Prolonged thiazolidinedione therapy does not reverse fat loss in
464 patients with familial partial lipodystrophy, Dunnigan variety. *Diabetes Obes Metab* **10**, 1275-
465 1276 (2008). <https://doi.org:10.1111/j.1463-1326.2008.00978.x>
- 466 29 Luedtke, A. *et al.* Thiazolidinedione response in familial lipodystrophy patients with LMNA
467 mutations: a case series. *Horm Metab Res* **44**, 306-311 (2012). <https://doi.org:10.1055/s-0031-1301284>
- 468 30 Agostini, M. *et al.* A Pharmacogenetic Approach to the Treatment of Patients With PPARG
469 Mutations. *Diabetes* **67**, 1086-1092 (2018). <https://doi.org:10.2337/db17-1236>
- 470 31 Francis, G. A. *et al.* Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian
471 kindred with familial partial lipodystrophy type 3 (FPLD3). *BMC Med Genet* **7**, 3 (2006).
472 <https://doi.org:10.1186/1471-2350-7-3>
- 473 32 Savage, D. B. *et al.* Human metabolic syndrome resulting from dominant-negative mutations in
474 the nuclear receptor peroxisome proliferator-activated receptor-gamma. *Diabetes* **52**, 910-917
475 (2003). <https://doi.org:10.2337/diabetes.52.4.910>
- 476 33 Hashimoto, N. *et al.* A case of type A insulin resistance associated with heterozygous Asn462Ser
477 mutation of the insulin receptor gene. *Diabetology International* **3**, 239-243 (2012).
478 <https://doi.org:10.1007/s13340-012-0079-6>
- 479 34 Jo, W. *et al.* Development of endometrial carcinoma in a patient with leprechaunism (donohue
480 syndrome). *Clinical pediatric endocrinology : case reports and clinical investigations : official*
481 *journal of the Japanese Society for Pediatric Endocrinology* **22**, 33-38 (2013).
482 <https://doi.org:10.1292/cpe.22.33>
- 483 35 Perge, K. *et al.* Intrauterine Growth Restriction and Hypertrophic Cardiomyopathy as Prenatal
484 Ultrasound Findings in a Case of Leprechaunism. *Mol Syndromol* **11**, 223-227 (2020).
485 <https://doi.org:10.1159/000509837>
- 486

- 487 36 Plamper, M., Gohlke, B., Schreiner, F. & Woelfle, J. Mecasermin in Insulin Receptor-Related
488 Severe Insulin Resistance Syndromes: Case Report and Review of the Literature. *International*
489 *journal of molecular sciences* **19** (2018). <https://doi.org/10.3390/ijms19051268>
- 490 37 Carmody, D., Ladsaria, S. S., Buikema, R. K., Semple, R. K. & Greeley, S. A. Successful rhIGF1
491 treatment for over 5 years in a patient with severe insulin resistance due to homozygous insulin
492 receptor mutation. *Diabet Med* **33**, e8-e12 (2016). <https://doi.org/10.1111/dme.12884>
- 493 38 de Kerdanet, M. *et al.* Ten-year improvement of insulin resistance and growth with recombinant
494 human insulin-like growth factor 1 in a patient with insulin receptor mutations resulting in
495 leprechaunism. *Diabetes Metab* **41**, 331-337 (2015).
496 <https://doi.org/10.1016/j.diabet.2014.11.001>
- 497 39 Weber, D. R., Stanescu, D. E., Semple, R., Holland, C. & Magge, S. N. Continuous subcutaneous
498 IGF-1 therapy via insulin pump in a patient with Donohue syndrome. *J Pediatr Endocrinol Metab*
499 **27**, 1237-1241 (2014). <https://doi.org/10.1515/jpem-2013-0402>
- 500 40 Regan, F. M. *et al.* Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF
501 binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. *J*
502 *Clin Endocrinol Metab* **95**, 2113-2122 (2010). <https://doi.org/10.1210/jc.2009-2088>
- 503 41 Vestergaard, H., Rossen, M., Urhammer, S. A., Müller, J. & Pedersen, O. Short- and long-term
504 metabolic effects of recombinant human IGF-I treatment in patients with severe insulin
505 resistance and diabetes mellitus. *Eur J Endocrinol* **136**, 475-482 (1997).
506 <https://doi.org/10.1530/eje.0.1360475>
- 507 42 Kuzuya, H. *et al.* Trial of insulinlike growth factor I therapy for patients with extreme insulin
508 resistance syndromes. *Diabetes* **42**, 696-705 (1993). <https://doi.org/10.2337/diab.42.5.696>
- 509 43 Metwalley, K. A. & Farghaly, H. S. Berardinelli-Seip syndrome type 1 in an Egyptian child. *Indian J*
510 *Hum Genet* **20**, 75-78 (2014). <https://doi.org/10.4103/0971-6866.132762>
- 511 44 Kirel, B. *et al.* A case of Donohue syndrome "Leprechaunism" with a novel mutation in the insulin
512 receptor gene. *Turk Pediatri Ars* **52**, 226-230 (2017).
513 <https://doi.org/10.5152/TurkPediatriArs.2017.3193>
- 514 45 Saito-Hakoda, A. *et al.* A follow-up during puberty in a Japanese girl with type A insulin resistance
515 due to a novel mutation in INSR. *Clinical pediatric endocrinology : case reports and clinical*
516 *investigations : official journal of the Japanese Society for Pediatric Endocrinology* **27**, 53-57
517 (2018). <https://doi.org/10.1297/cpe.27.53>
- 518 46 Kawana, Y., Imai, J., Sawada, S., Yamada, T. & Katagiri, H. Sodium-Glucose Cotransporter 2
519 Inhibitor Improves Complications of Lipodystrophy: A Case Report. *Ann Intern Med* **166**, 450-451
520 (2017). <https://doi.org/10.7326/l16-0372>
- 521 47 Hamaguchi, T. *et al.* Treatment of a case of severe insulin resistance as a result of a PIK3R1
522 mutation with a sodium-glucose cotransporter 2 inhibitor. *Journal of diabetes investigation* **9**,
523 1224-1227 (2018). <https://doi.org/10.1111/jdi.12825>
- 524 48 Ciudin, A. *et al.* Successful treatment for the Dunnigan-type familial partial lipodystrophy with
525 Roux-en-Y gastric bypass. *Clin Endocrinol (Oxf)* **75**, 403-404 (2011).
526 <https://doi.org/10.1111/j.1365-2265.2011.04057.x>
- 527 49 Grundfest-Broniatowski, S., Yan, J., Kroh, M., Kilim, H. & Stephenson, A. Successful Treatment of
528 an Unusual Case of FPLD2: The Role of Roux-en-Y Gastric Bypass-Case Report and Literature
529 Review. *J Gastrointest Surg* **21**, 739-743 (2017). <https://doi.org/10.1007/s11605-016-3300-2>
- 530 50 Kozusko, K. *et al.* Clinical and molecular characterization of a novel PLIN1 frameshift mutation
531 identified in patients with familial partial lipodystrophy. *Diabetes* **64**, 299-310 (2015).
532 <https://doi.org/10.2337/db14-0104>
- 533 51 Kadowaki, T. *et al.* Two mutant alleles of the insulin receptor gene in a patient with extreme
534 insulin resistance. *Science* **240**, 787-790 (1988). <https://doi.org/10.1126/science.2834824>
- 535 52 Yoshimasa, Y. *et al.* Insulin-resistant diabetes due to a point mutation that prevents insulin
536 proreceptor processing. *Science* **240**, 784-787 (1988). <https://doi.org/10.1126/science.3283938>

- 537 53 Shackleton, S. *et al.* LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. *Nat Genet* **24**,
538 153-156 (2000). <https://doi.org/10.1038/72807>
- 539 54 Lightbourne, M. & Brown, R. J. Genetics of Lipodystrophy. *Endocrinol Metab Clin North Am* **46**,
540 539-554 (2017). <https://doi.org/10.1016/j.ecl.2017.01.012>
- 541 55 Barroso, I. *et al.* Dominant negative mutations in human PPARgamma associated with severe
542 insulin resistance, diabetes mellitus and hypertension. *Nature* **402**, 880-883 (1999).
543 <https://doi.org/10.1038/47254>
- 544 56 Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T. & Leff, T. PPARG F388L, a transactivation-
545 deficient mutant, in familial partial lipodystrophy. *Diabetes* **51**, 3586-3590 (2002).
546 <https://doi.org/10.2337/diabetes.51.12.3586>
- 547 57 Majithia, A. R. *et al.* Prospective functional classification of all possible missense variants in
548 PPARG. *Nat Genet* **48**, 1570-1575 (2016). <https://doi.org/10.1038/ng.3700>
- 549 58 Mikita, J. S. *et al.* Determining the Suitability of Registries for Embedding Clinical Trials in the
550 United States: A Project of the Clinical Trials Transformation Initiative. *Ther Innov Regul Sci* **55**, 6-
551 18 (2021). <https://doi.org/10.1007/s43441-020-00185-5>
- 552 59 Kidwell, K. M. *et al.* Application of Bayesian methods to accelerate rare disease drug
553 development: scopes and hurdles. *Orphanet J Rare Dis* **17**, 186 (2022).
554 <https://doi.org/10.1186/s13023-022-02342-5>
- 555 60 Partington, G., Cro, S., Mason, A., Phillips, R. & Cornelius, V. Design and analysis features used in
556 small population and rare disease trials: A targeted review. *J Clin Epidemiol* **144**, 93-101 (2022).
557 <https://doi.org/10.1016/j.jclinepi.2021.12.009>
- 558 61 Adams, H. R. *et al.* A novel, hybrid, single- and multi-site clinical trial design for CLN3 disease, an
559 ultra-rare lysosomal storage disorder. *Clin Trials* **16**, 555-560 (2019).
560 <https://doi.org/10.1177/1740774519855715>
- 561 62 <<https://www.eclip-web.org/information/registry/>> (
562 63 Doherty, D. A. *et al.* Registry randomised trials: a methodological perspective. *BMJ open* **13**,
563 e068057 (2023). <https://doi.org/10.1136/bmjopen-2022-068057>
- 564 64 James, S., Rao, S. V. & Granger, C. B. Registry-based randomized clinical trials--a new clinical trial
565 paradigm. *Nat Rev Cardiol* **12**, 312-316 (2015). <https://doi.org/10.1038/nrcardio.2015.33>
566

567

Tables

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603


Study types	Number of studies
Case reports	21
Non-randomised experimental study	10
Case series	8
Study Quality*	Number of studies
Good	0
Fair	15
Poor	28
Phenotypes	Number of participants
Partial lipodystrophy	90 (72 <i>LMNA</i> , 15 <i>PPARG</i> , 2 <i>PLIN1</i> , 1 <i>PIK3R1</i>)
Generalised lipodystrophy	56 (21 <i>AGPAT2</i> , 21 <i>BSCL2</i> , 1 <i>PTRF</i> , 2 <i>LMNA</i>)
Insulin receptor	17 (7 Monoallelic, 10 Biallelic)
Intervention	Number of participants
Metreleptin	111 (71/40/0)
rhIGF-1 or rhIGF-1/IGFBP3 composite	15 (0/0/15)
Thiazolidinedione	13 (12/1/0)
Metformin	5 (2/1/2)
Bariatric surgery	4 (4/0/0)
SGLT2i	2 (1/1/0)

Table 1: Summary characteristics of included studies.

*Based on NHLBI quality assessment tool; #Numbers in brackets are for partial lipodystrophy/generalised lipodystrophy/ insulin receptor individuals respectively. Abbreviations: rhIGF-1, recombinant human insulin-like growth factor 1; IGFBP3, insulin-like growth factor binding protein 3; SGLT2i, sodium-glucose co-transporter-2 inhibitor

604
605
606
607
608


Figures



609
610
611
612
613

Figure 1: Flow diagram of publications evaluated based on the search strategy.

614
615
616
617
618



619
620

621 **Figure 2: Effects of metreleptin in monogenic forms of lipodystrophy** Least square mean
622 change in (A) Hemoglobin A1c (A1c), (B) \log_{10} serum triglyceride concentration and (C) Body
623 Mass Index (BMI) in patients with partial lipodystrophy, generalized lipodystrophy, all forms
624 of lipodystrophy, and subgroups with *PPARG*, *LMNA*, *BSC1.2*, and *AGPAT2* mutations.

625


626

627

628

629

630



631

632 **Figure 3: Effects of recombinant human Insulin-like Growth Factor-1 (rhIGF) alone or in**


633 **combination with Insulin-like Growth Factor Binding Protein-3 (IGFBP3) in patients**

634 **with *INSR* mutations** Least square mean change in hemoglobin A1c (A1c), in all patients

635 **with *INSR* mutations, and in subgroups with biallelic and monoallelic mutations.**

636

637



638

639 **Figure 4: Effects of thiazolidinediones in monogenic forms of lipodystrophy** Least

640 square mean change in (A) Hemoglobin A1c (A1c), (B) Log₁₀ serum triglyceride

641 concentration and (C) Body Mass Index (BMI) in patients with partial lipodystrophy,

642 generalized lipodystrophy, all forms of lipodystrophy, and subgroups with *PPARG*, and

643 *LMNA* mutations.

644

Supplemental Tables

645

Disease	Gene Names and Variants	Treatments
Lipodystrophy	<i>LMNA</i>	Medication
Severe Insulin resistance	Lamin A/C	Therapy
Type A insulin resistance	<i>BSCL2</i>	Medical management
Donohue syndrome	Seipin	Treatment
Rabson Mendenhall syndrome	<i>AGPAT2</i>	SGLT2 inhibitor
Leprechaun	<i>PTRF</i>	SGLT2i
Leprechaunism	<i>CAVIN1</i>	SGLT-2 inhibitor
FPLD	<i>CAV1</i>	SGLT-2i
FPLD2	<i>ZMPSTE24</i>	Sodium Glucose Transporter 2 inhibitor
FPLD3	<i>PPARG</i>	Dapagliflozin
FPLD4	<i>PLIN1</i>	Empagliflozin
FPLD5	<i>MFN2</i>	Ertagliflozin
FPLD6	<i>CIDEA</i>	Canagliflozin
FPLD7	<i>LIPE</i>	Flozin
SHORT syndrome	<i>PCYT1A</i>	Thiazolidinedione
SOFT syndrome	<i>INSR</i>	PPARγ Agonist
vSOFT	<i>AKT2</i>	PPAR gamma agonist
Werner syndrome	<i>PIK3R1</i>	TZD
Bloom syndrome	<i>AKT2</i>	Rosiglitazone
MOPDII	<i>WRN</i>	Pioglitazone
Osteodysplastic primordial dwarfism of Majewski type 2	<i>BLM</i>	Troglitazone
Alstrom syndrome	<i>NSMCE2</i>	GLP1RA
MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHY SYNDROME	<i>POLD1</i>	GLP1 Receptor Agonists
MDPL	<i>PCNT</i>	GLP-1 Receptor Agonists
Mandibuloacral dysplasia	<i>POC1A</i>	GLP-1RA
MARFANOID-PROGEROID-LIPODYSTROPHY SYNDROME	<i>ALMS1</i>	Exenatide
MFLS	<i>PSMB8</i>	Liraglutide
PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 1	<i>FBN1</i>	Lixisenatide
PRAAS1		Semaglutide
		Dulaglutide
		Albiglutide
		Bariatric surgery
		Obesity Surgery
		Weight reduction surgery

	gastric band
	Roux-en-Y
	Gastric sleeve
	Gastric bypass
	metabolic surgery
	IGF-1
	rhIGF-1
	somatokine
	recombinant human insulin like growth factor 1
	Insulin like growth factor 1
	Increlex
	Mecasermin
	IGF-1/IGFBP3
	IGF1
	rhIGF1
	IGF1/IGFBP3
	leptin
	rhleptin
	metreleptin
	Myalept
	Myalepta

646
647
648
649

Supplemental Table 1: Descriptors of diseases, gene names and treatments included in the initial search

650

651

652

653

654



Supplemental Table
2 Quality assessmen

655

656

657

658

Supplemental Table 2: Detailed Quality Assessment of Included Studies

659

		Treatment						Total
		rhIGF-1 or rhIGF-1/IGFBP3 composite	SGLT2i	TZD	Bariatric surgery	Metformin	Metreleptin	
Gene	<i>AGPAT2</i>	0	0	0	0	1	20	21
	<i>BSC2</i>	0	1	1	0	0	19	21
	<i>PTRF</i>	0	0	0	0	0	1	1
	<i>LMNA</i> (<i>progeroid</i>)	0	0	0	0	0	2	2
	<i>LMNA</i> (<i>FPL</i>)	0	0	9	2	2	59	72
	<i>PPARG</i>	0	0	5	0	0	10	15
	<i>PLIN1</i>	0	0	0	2	0	0	2
	<i>PIK3R1</i>	0	1	0	0	0	0	1
	<i>INSR</i>	15	0	0	0	2	0	17
<i>All partial LD</i>		--	1	14	4	2	71	90
<i>All generalised LD</i>		--	1	1	0	1	40	43
<i>All LD</i>		--	2	15	4	3	111	135

660

661 **Supplemental Table 3: Number of individuals by intervention and genotype in included**

662 **studies** Abbreviations: rhIGF-1, recombinant human insulin-like growth factor 1; IGFBP3,

663 insulin-like growth factor binding protein 3; SGLT2i, sodium-glucose co-transporter-2

664 inhibitor; TZD, thiazolidinedione; FPL = Familial Partial Lipodystrophy

665
666
667
668
669
670
671



Supplemental Table
4 Summary stats 14 /

672
673
674
675


Supplemental Table 4: Summary statistics of extracted data

676

Supplemental Figures

677

678



679

680

681


Supplemental Figure 1: Effects of Metreleptin therapy on glycated

682

haemoglobin (A1c) by genotype

683


684
685
686
687



688
689
690
691
692
693
694
695
696
697
698

Supplemental Figure 2: Effects of Metreleptin therapy on serum triglyceride concentration by genotype


699
700
701
702
703
704



705
706
707
708
709
710
711
712

Supplemental Figure 3: Effects of Metreleptin therapy on body mass index (BMI) by genotype


713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729



730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750

Supplemental Figure 4: Effects of recombinant IGF-1 or IGF-1 plus IGFBP3 therapy on glycated haemoglobin (A1c) in monallelic and biallelic insulin receptoropathy


751
752
753
754
755
756



757
758
759
760
761
762
763
764
765
766
767
768
769
770

Supplemental Figure 5: Effects of thiazolidinedione therapy by genotype





771
772
773
774
775



776
777
778
779
780
781
782
783
784
785
786
787
788
789

Supplemental Figure 6: Effects of bariatric surgery by genotype


790
791
792
793
794



795
796
797
798
799
800
801
802
803
804
805
806
807

Supplemental Figure 7: Effects of metformin therapy by genotype

808
809
810
811
812
813



814
815
816
817

Supplemental Figure 8: Effects of SGLT2 inhibitor therapy by genotype